Effect of SGLT2 inhibitor on lactic acid,ketone bodies,glucagon in type 2 diabetes mellitus patients.

Effect of SGLT2 inhibitor on lactic acid,ketone bodies,glucagon in type 2 diabetes mellitus patients. - Effect of SGLT2 inhibitor on lactic acid,ketone bodies,glucagon in type 2 diabetes mellitus patients.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015759

Enrollment

Registered

2014-12-16

Start date

2014-11-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

SGLT2 inhibitor

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)age 20 to less than 90. 2)ongoing treatment by sulfonylurea, biguanide, DPP4 inhibitor, thiazolidine, or insulin therapy.

Exclusion criteria

Exclusion criteria: 1)Type 1 diabetes mellitus. 2) having diabetic ketoacidosis, nonketotic hyperosmolar coma, infection. 3) being pregnant or possibly pregnant.

Design outcomes

Primary

Measure	Time frame
Change of serum lactic acid, ketone bodies,CPR,and glucagon value comparing with baseline.	—

Secondary

Measure	Time frame
Comparing with baseline change of urinalysis (sodium, potassium, glucose,osmotic pressure),uric acid,PRA,PAC,ACTH,cortisol,AVP,osmotic pressure.	—

Countries

Japan

Contacts

Public ContactKenichi Hashimoto

Gifu University Graduate School of Medicine Department of Endoclinology

kh0123789@outlook.jp058-230-6523

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026